32,091 Shares in Astrazeneca Plc $AZN Bought by Third View Private Wealth LLC

Key Points

• Third View Private Wealth LLC opened a new position in AstraZeneca (NYSE:AZN), buying 32,091 shares in Q4 valued at about $2.95 million per its latest 13F filing.
• AstraZeneca paid a dividend of $1.595 per share on March 23 (record date Feb 20), with the article reporting a 156.0% yield and a payout ratio of 74.83%.
• Analyst sentiment is mixed-but-positive: nine analysts rate AZN a Buy and one a Sell, giving an overall "Moderate Buy" consensus and an average target price of $95.75.

Third View Private Wealth LLC bought a new position in shares of Astrazeneca Plc (NYSE:AZN - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 32,091 shares of the company's stock, valued at approximately $2,950,000.

Other hedge funds have also bought and sold shares of the company. Bangor Savings Bank increased its stake in Astrazeneca by 102.7% in the fourth quarter. Bangor Savings Bank now owns 304 shares of the company's stock valued at $28,000 after purchasing an additional 154 shares in the last quarter. Triumph Capital Management bought a new stake in Astrazeneca in the third quarter valued at $25,000. YANKCOM Partnership bought a new stake in Astrazeneca in the fourth quarter valued at $31,000. Rakuten Investment Management Inc. bought a new stake in Astrazeneca in the third quarter valued at $31,000. Finally, JPL Wealth Management LLC bought a new stake in Astrazeneca in the third quarter valued at $35,000. Institutional investors own 20.35% of the company's stock.

Astrazeneca Price Performance

NYSE:AZN opened at $202.35 on Tuesday. The company has a quick ratio of 0.72, a current ratio of 0.94 and a debt-to-equity ratio of 0.51. The stock has a market cap of $313.82 billion, a PE ratio of 34.86, a price-to-earnings-growth ratio of 1.54 and a beta of 0.35. Astrazeneca Plc has a one year low of $132.32 and a one year high of $212.71.

Astrazeneca Dividend Announcement

The firm also recently announced a dividend, which was paid on Monday, March 23rd. Stockholders of record on Friday, February 20th were given a dividend of $1.595 per share. The ex-dividend date of this dividend was Friday, February 20th. This represents a dividend yield of 156.0%. Astrazeneca's payout ratio is presently 74.83%.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. TD Cowen reaffirmed a "buy" rating on shares of Astrazeneca in a research report on Wednesday, March 18th. Morgan Stanley reaffirmed an "overweight" rating on shares of Astrazeneca in a research report on Wednesday, April 8th. Wall Street Zen lowered Astrazeneca from a "buy" rating to a "hold" rating in a research report on Saturday, April 4th. Barclays reaffirmed an "overweight" rating on shares of Astrazeneca in a research report on Tuesday, January 6th. Finally, Citigroup assumed coverage on Astrazeneca in a research report on Tuesday, January 27th. They issued a "buy" rating for the company. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $95.75.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca Plc (NYSE:AZN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.